A new approach to weight loss management

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The SMARTer trial is a randomized controlled trial that compares an adaptive weight loss intervention to the standard Diabetes Prevention Program (DPP) and usual care. It aims to determine if the SMARTer intervention can achieve similar weight loss results as DPP while being more cost-effective. Participants will be assessed at multiple time points over a year to evaluate weight loss outcomes and the economic feasibility of the interventions. The study seeks to provide valuable insights into the affordability and effectiveness of behavioral weight loss strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Over 18 years old
* BMI of ≥25, weight \<396 lbs
* Must own a Smartphone, and be willing to install the SMARTer app
* Not enrolled in a formal weight loss program

Exclusion Criteria:

* Cerebrovascular accident or myocardial infarction within six months of enrollment
* Diabetes treated with insulin
* Pregnancy, lactation or intended pregnancy
* Active suicidal ideation
* Anorexia or bulimia
* Requiring an assistive device for mobility
* Taking weight loss medications, such as GLP-1 agonists

Where it's running

• Florida State University
  Tallahassee, Florida, United States Recruiting

Study contacts

• Principal investigator: Bonnie Spring, PhD — Florida State University
• Study coordinator: Keri A Gladhill, PhD
• Email: keri.gladhill@med.fsu.edu
• Phone: 850-645-5401

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.